Edwards Lifesciences Corporation (EW) fair value analysis
S&P 500 · Updated 2026-10-19
EW price how computed
Forward Fair Value verdict
UndervaluedEW is trading at a 10–25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $85.21
- Sector
- Healthcare
- 12-month range
- $75.87–$95.18
- Market cap
- $49.1B
- From 52-week high
- -10.5%
- Shares outstanding
- 576M
- Rank in Healthcare by discount to fair value
- #33 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Edwards Lifesciences Corporation manufactures and distributes medical devices and therapies focused on structural heart disease, critical care monitoring, and surgical applications. The company operates globally across North America, Europe, Asia Pacific, and other international markets.
EW currently ranks #33 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $49.1B
- P/E (trailing)
- 30x
- Revenue (TTM)
- $6.51B
- Net margin
- 15.4%
- EPS (TTM)
- $2.81
- Gross margin
- 77.6%
- Debt / equity
- 0.07
- Revenue growth (3-yr avg)
- 13.3%
- Shares outstanding
- 576M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Stable
- 52-week position
- The lower-middle quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 47 · neutral
- 50-day average
- $88.42
- 200-day average
- $85.14
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-04 (post-market)
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+6.8%)
2026-03 ▲ beat (+6.8%)
2025-12 ▼ miss (-6.4%)
2025-09 ▲ beat (+13.6%)
2025-06 ▲ beat (+8.1%)
2025-03 ▲ beat (+6.7%)
2024-12 ▲ beat (+6.4%)
2024-09 ▲ beat (+13.6%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 22 buy · 7 hold · 0 sell (29 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $102
- Target vs last price
- +19.7%
What our data shows for EW
- Our model validated 17 trailing price-to-earnings windows for EW, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $75.87–$95.18.
- The 14-day relative strength index sits at a neutral 47.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for EW
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent EW news
TickrTrends' derived news-sentiment signal for EW is currently leaning positive, computed from recent coverage.
- Edwards Lifesciences (EW) Gains FDA Clearance for AUTUS Size-Adjustable Valve (gurufocus.com, 2026-10-01)
TickrTrends take: Edwards Lifesciences received FDA clearance for its AUTUS size-adjustable valve, expanding its structural heart portfolio with a product designed to address a significant clinical need. Given that TickrTrends currently rates EW as undervalued within the Healthcare sector, investors focused on valuation should monitor whether this regulatory approval translates into meaningful revenue contributions and market adoption that could justify the current assessment. The commercial success of this new valve platform will be an important factor in tracking whether EW's fundamentals support its undervalued designation going forward. - Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript (seekingalpha.com, 2026-09-16)
TickrTrends take: Edwards Lifesciences' participation in the Deutsche Bank Healthcare Summit provides an opportunity for investors to assess management's strategic positioning and capital allocation plans against its current undervalued assessment. For valuation-focused readers, such presentations typically reveal insights into growth drivers, margin expansion potential, and competitive positioning that could support or challenge the undervalued verdict in the Healthcare sector. Monitoring management commentary on innovation pipelines and market expansion during such forums can help gauge whether the current valuation discount adequately reflects the company's future earning power. - Is Edwards Lifesciences Stock Underperforming the Dow? (finance.yahoo.com, 2026-09-08)
TickrTrends take: Edwards Lifesciences operates in the Healthcare sector and is currently rated as Undervalued according to TickrTrends' derived verdict. The question of whether EW is underperforming the Dow relates directly to the gap between its stock price performance and its underlying valuation metrics, which TickrTrends assesses as favorable. A valuation-focused reader should monitor whether the stock's relative underperformance reflects genuine weakness in the business fundamentals or represents a market inefficiency that could resolve as investors reassess the company's intrinsic worth.
What people are saying
Follow the EW conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — TickrTrends' derived indicators for EW show a shift in momentum this week, with the RSI zone moving from oversold to neutral territory. The healthcare sector stock maintains an undervalued position according to current valuation metrics. This change in the RSI indicator suggests the stock may be stabilizing after previously oversold conditions.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is EW stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), EW is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is EW's TickrTrends verdict?
EW's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does EW compare to other Healthcare stocks?
EW ranks #33 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is EW overbought or oversold?
EW's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does EW report earnings next?
EW's next earnings report is scheduled for 2026-11-04 (post-market), per the published earnings calendar.
Does EW usually beat earnings estimates?
Over its last 8 reported quarters EW beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about EW?
Of 29 analysts covering EW, 22 rate it a buy, 7 a hold and 0 a sell - buy-leaning, with a consensus price target of $102 (+19.7% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
EW vs ASND · EW vs BDX · EW vs BTSG · EW vs DVA · EW vs HALO